Cargando…

Transient opening of trimeric prefusion RSV F proteins

The respiratory syncytial virus (RSV) F glycoprotein is a class I fusion protein that mediates viral entry and is a major target of neutralizing antibodies. Structures of prefusion forms of RSV F, as well as other class I fusion proteins, have revealed compact trimeric arrangements, yet whether thes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gilman, Morgan S. A., Furmanova-Hollenstein, Polina, Pascual, Gabriel, B. van ‘t Wout, Angélique, Langedijk, Johannes P. M., McLellan, Jason S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506550/ https://www.ncbi.nlm.nih.gov/pubmed/31068578 http://dx.doi.org/10.1038/s41467-019-09807-5

Ejemplares similares

A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism
por: Krarup, Anders, et al.
Publicado: (2015)

Structure-Based Design of Prefusion-Stabilized Filovirus Glycoprotein Trimers
por: Rutten, Lucy, et al.
Publicado: (2020)

Structural basis for recognition of the central conserved region of RSV G by neutralizing human antibodies
por: Jones, Harrison G., et al.
Publicado: (2018)

Improved epitope resolution of the prefusion trimer-specific antibody AM14 bound to the RSV F glycoprotein
por: Harshbarger, Wayne, et al.
Publicado: (2021)

Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein
por: Gilman, Morgan S. A., et al.
Publicado: (2015)

Protection of calves by a prefusion-stabilized bovine RSV F vaccine
por: Zhang, Baoshan, et al.
Publicado: (2017)

Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice
por: van der Fits, Leslie, et al.
Publicado: (2020)

Fusing safety and efficacy: A maternal bivalent RSV prefusion F vaccine
por: Miller, Ann M., et al.
Publicado: (2023)

Adjuvant Selection for Influenza and RSV Prefusion Subunit Vaccines
por: Isaacs, Ariel, et al.
Publicado: (2021)

Structure and immune recognition of trimeric prefusion HIV-1 Env
por: Pancera, Marie, et al.
Publicado: (2014)

A human antibody potently neutralizes RSV by targeting the conserved hydrophobic region of prefusion F
por: Yi, Chunyan, et al.
Publicado: (2023)

Soluble prefusion-closed HIV-envelope trimers with glycan-covered bases
por: Olia, Adam S., et al.
Publicado: (2023)

The respiratory syncytial virus (RSV) prefusion F‐protein functional antibody repertoire in adult healthy donors
por: Andreano, Emanuele, et al.
Publicado: (2021)

RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models
por: Cox, Freek, et al.
Publicado: (2023)

1632. Bivalent RSV Prefusion F-Based Subunit Vaccine Generates High Neutralizing Titers in Older Adults
por: Fukushima, Yasushi, et al.
Publicado: (2023)

The 3.1-Angstrom Cryo-electron Microscopy Structure of the Porcine Epidemic Diarrhea Virus Spike Protein in the Prefusion Conformation
por: Wrapp, Daniel, et al.
Publicado: (2019)

Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state
por: Rossey, Iebe, et al.
Publicado: (2017)

Alternative conformations of a major antigenic site on RSV F
por: Jones, Harrison G., et al.
Publicado: (2019)

Structure of the rabies virus glycoprotein trimer bound to a prefusion-specific neutralizing antibody
por: Callaway, Heather M., et al.
Publicado: (2022)

Monomeric prefusion structure of an extremophile gamete fusogen and stepwise formation of the postfusion trimeric state
por: Feng, Juan, et al.
Publicado: (2022)

Structure-based design of prefusion-stabilized human metapneumovirus fusion proteins
por: Hsieh, Ching-Lin, et al.
Publicado: (2022)

Corrigendum: Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state
por: Rossey, Iebe, et al.
Publicado: (2017)

1936. Efficacy of One Dose of the Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Adults ≥ 60 Years of Age Persists for 2 RSV Seasons
por: Ison, Michael G, et al.
Publicado: (2023)

Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation
por: Wrapp, Daniel, et al.
Publicado: (2020)

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
por: Wrapp, Daniel, et al.
Publicado: (2020)

Immunogenicity and protective efficacy of RSV G central conserved domain vaccine with a prefusion nanoparticle
por: Rainho-Tomko, Jennifer N., et al.
Publicado: (2022)

2755. Phase 1/2, First-in-Human Study of the Safety, Tolerability, and Immunogenicity of an RSV Prefusion F-Based Subunit Vaccine Candidate
por: Schmoele-Thoma, Beate, et al.
Publicado: (2019)

Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability
por: Kong, Leopold, et al.
Publicado: (2016)

1942. Potential Public Health Impact of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of RSV among US Infants
por: Hanau, Ahuva, et al.
Publicado: (2023)

Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial
por: Houser, Katherine V., et al.
Publicado: (2022)

A Protective and Safe Intranasal RSV Vaccine Based on a Recombinant Prefusion-Like Form of the F Protein Bound to Bacterium-Like Particles
por: Rigter, Alan, et al.
Publicado: (2013)

Enhancing Anti-G Antibody Induction by a Live Single-Cycle Prefusion F—Expressing RSV Vaccine Improves In Vitro and In Vivo Efficacy
por: Lamichhane, Pramila, et al.
Publicado: (2022)

LB745. Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults ≥ 60 Years of Age (YOA)
por: Ison, Michael G, et al.
Publicado: (2022)

Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants
por: Liu, Haitao, et al.
Publicado: (2021)

Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV-Seropositive Children 12–24 Months
por: Stuart, Arabella S V, et al.
Publicado: (2022)

The microtubule stabilizer patupilone counteracts ionizing radiation-induced matrix metalloproteinase activity and tumor cell invasion
por: Furmanova-Hollenstein, Polina, et al.
Publicado: (2013)

Continuous flexibility analysis of SARS-CoV-2 spike prefusion structures
por: Melero, Roberto, et al.
Publicado: (2020)

Continuous flexibility analysis of SARS-CoV-2 Spike prefusion structures
por: Melero, Roberto, et al.
Publicado: (2020)

Recombinant Soluble Respiratory Syncytial Virus F Protein That Lacks Heptad Repeat B, Contains a GCN4 Trimerization Motif and Is Not Cleaved Displays Prefusion-Like Characteristics
por: Widjaja, Ivy, et al.
Publicado: (2015)

The SARS-CoV-2 spike protein reversibly samples an open-trimer conformation exposing novel epitopes
por: Shoemaker, Sophie R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ofrl9i6fssbjnescepa043q37t